Vyne Therapeutics Inc (NASDAQ:VYNE) — Market Cap & Net Worth
Market Cap & Net Worth: Vyne Therapeutics Inc (VYNE)
Vyne Therapeutics Inc (NASDAQ:VYNE) has a market capitalization of $22.03 Million ($22.03 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24739 globally and #5215 in its home market, demonstrating a 3311.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vyne Therapeutics Inc's stock price $30.45 by its total outstanding shares 33352858 (33.35 Million). Review how much free cash does Vyne Therapeutics Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
Vyne Therapeutics Inc Market Cap History: 2018 to 2026
Vyne Therapeutics Inc's market capitalization history from 2018 to 2026. Data shows change from $9.89 Billion to $1.02 Billion (-39.07% CAGR).
Index Memberships
Vyne Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #703 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2319 of 3165 |
Weight: Vyne Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vyne Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vyne Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
33.94x
Vyne Therapeutics Inc's market cap is 33.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $9.89 Billion | $10.64 Million | -$51.45 Million | 929.87x | N/A |
| 2019 | $11.14 Billion | $1.75 Million | -$70.46 Million | 6367.16x | N/A |
| 2020 | $3.79 Billion | $20.99 Million | -$255.57 Million | 180.74x | N/A |
| 2021 | $612.36 Million | $931.00K | -$73.33 Million | 657.74x | N/A |
| 2022 | $90.05 Million | $477.00K | -$23.21 Million | 188.79x | N/A |
| 2023 | $77.71 Million | $424.00K | -$28.45 Million | 183.28x | N/A |
| 2024 | $111.73 Million | $501.00K | -$39.83 Million | 223.02x | N/A |
| 2025 | $19.35 Million | $570.00K | -$26.48 Million | 33.94x | N/A |
Competitor Companies of VYNE by Market Capitalization
Companies near Vyne Therapeutics Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Vyne Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Vyne Therapeutics Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Vyne Therapeutics Inc's market cap moved from $9.89 Billion to $ 1.02 Billion, with a yearly change of -39.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.02 Billion | +5149.09% |
| 2025 | $19.35 Million | -82.68% |
| 2024 | $111.73 Million | +43.78% |
| 2023 | $77.71 Million | -13.70% |
| 2022 | $90.05 Million | -85.29% |
| 2021 | $612.36 Million | -83.86% |
| 2020 | $3.79 Billion | -65.95% |
| 2019 | $11.14 Billion | +12.62% |
| 2018 | $9.89 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Vyne Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.03 Million USD |
| MoneyControl | $22.03 Million USD |
| MarketWatch | $22.03 Million USD |
| marketcap.company | $22.03 Million USD |
| Reuters | $22.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vyne Therapeutics Inc
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pa… Read more